vs
Side-by-side financial comparison of MID PENN BANCORP INC (MPB) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
MID PENN BANCORP INC is the larger business by last-quarter revenue ($62.0M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). MID PENN BANCORP INC runs the higher net margin — 31.4% vs -83.0%, a 114.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 30.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 21.1%).
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MPB vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.0M | $57.3M |
| Net Profit | $19.4M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 43.6% | -82.2% |
| Net Margin | 31.4% | -83.0% |
| Revenue YoY | 30.8% | 36.9% |
| Net Profit YoY | 47.0% | -9.6% |
| EPS (diluted) | $0.83 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.0M | $57.3M | ||
| Q3 25 | $61.8M | $51.3M | ||
| Q2 25 | $54.3M | $48.5M | ||
| Q1 25 | $47.7M | $32.7M | ||
| Q4 24 | $47.4M | $41.8M | ||
| Q3 24 | $45.3M | $33.3M | ||
| Q2 24 | $44.1M | $29.1M | ||
| Q1 24 | $42.3M | $26.0M |
| Q4 25 | $19.4M | $-47.5M | ||
| Q3 25 | $18.3M | $-52.9M | ||
| Q2 25 | $4.8M | $-46.6M | ||
| Q1 25 | $13.7M | $-49.5M | ||
| Q4 24 | $13.2M | $-43.3M | ||
| Q3 24 | $12.3M | $-43.6M | ||
| Q2 24 | $11.8M | $-32.3M | ||
| Q1 24 | $12.1M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 43.6% | -82.2% | ||
| Q3 25 | 39.3% | -102.6% | ||
| Q2 25 | 7.9% | -93.4% | ||
| Q1 25 | 35.2% | -143.7% | ||
| Q4 24 | 34.1% | -98.6% | ||
| Q3 24 | 32.8% | -132.0% | ||
| Q2 24 | 32.4% | -139.2% | ||
| Q1 24 | 34.8% | -538.7% |
| Q4 25 | 31.4% | -83.0% | ||
| Q3 25 | 29.6% | -103.1% | ||
| Q2 25 | 8.8% | -96.1% | ||
| Q1 25 | 28.8% | -151.4% | ||
| Q4 24 | 27.9% | -103.6% | ||
| Q3 24 | 27.1% | -131.2% | ||
| Q2 24 | 26.7% | -110.9% | ||
| Q1 24 | 28.7% | -544.4% |
| Q4 25 | $0.83 | $-0.73 | ||
| Q3 25 | $0.79 | $-0.82 | ||
| Q2 25 | $0.22 | $-0.75 | ||
| Q1 25 | $0.71 | $-0.81 | ||
| Q4 24 | $0.72 | $-0.71 | ||
| Q3 24 | $0.74 | $-0.73 | ||
| Q2 24 | $0.71 | $-0.55 | ||
| Q1 24 | $0.73 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $814.1M | $139.1M |
| Total Assets | $6.1B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M | ||
| Q1 24 | — | $201.2M |
| Q4 25 | $814.1M | $139.1M | ||
| Q3 25 | $796.3M | $148.8M | ||
| Q2 25 | $775.7M | $-11.9M | ||
| Q1 25 | $667.9M | $18.9M | ||
| Q4 24 | $655.0M | $21.7M | ||
| Q3 24 | $573.1M | $11.2M | ||
| Q2 24 | $559.7M | $39.3M | ||
| Q1 24 | $551.0M | $61.6M |
| Q4 25 | $6.1B | $480.2M | ||
| Q3 25 | $6.3B | $506.9M | ||
| Q2 25 | $6.4B | $372.7M | ||
| Q1 25 | $5.5B | $386.7M | ||
| Q4 24 | $5.5B | $392.3M | ||
| Q3 24 | $5.5B | $363.6M | ||
| Q2 24 | $5.4B | $381.8M | ||
| Q1 24 | $5.3B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.0M | $-25.4M |
| Free Cash FlowOCF − Capex | $71.8M | — |
| FCF MarginFCF / Revenue | 115.8% | — |
| Capex IntensityCapex / Revenue | 13.3% | — |
| Cash ConversionOCF / Net Profit | 4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $132.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.0M | $-25.4M | ||
| Q3 25 | $26.3M | $-26.6M | ||
| Q2 25 | $29.0M | $-23.3M | ||
| Q1 25 | $11.5M | $-40.4M | ||
| Q4 24 | $51.4M | $-18.8M | ||
| Q3 24 | $16.9M | $-25.2M | ||
| Q2 24 | $18.0M | $-29.1M | ||
| Q1 24 | $12.4M | $-40.7M |
| Q4 25 | $71.8M | — | ||
| Q3 25 | $24.3M | — | ||
| Q2 25 | $27.2M | — | ||
| Q1 25 | $8.8M | — | ||
| Q4 24 | $44.5M | — | ||
| Q3 24 | $16.8M | — | ||
| Q2 24 | $17.7M | — | ||
| Q1 24 | $12.1M | — |
| Q4 25 | 115.8% | — | ||
| Q3 25 | 39.4% | — | ||
| Q2 25 | 50.1% | — | ||
| Q1 25 | 18.4% | — | ||
| Q4 24 | 93.8% | — | ||
| Q3 24 | 37.1% | — | ||
| Q2 24 | 40.2% | — | ||
| Q1 24 | 28.5% | — |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | 14.6% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 6.08× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
